Krystal Biotech, Inc. (KRYS) Key Metrics
KRYS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $9.37B
- Enterprise value
- $9.28B
- P/E (TTM)
- 39.7 10-yr median 52.3
- Forward P/E
- 46.9
- PEG ratio
- —
- Price / sales
- 21.3 10-yr median 43.4
- Price / book
- 7.4 10-yr median 4.1
- EV / EBITDA
- 45.4
- Dividend yield
- —
- Beta
- 0.50
KRYS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKRYS valuation Price multiples at each fiscal year-end price.
KRYS returns How much profit the business earns on the capital it uses.
KRYS per-share figures Results divided by the shares outstanding at year-end.
KRYS financial health Debt, liquidity and how easily interest is covered.
KRYS efficiency & capital use Working capital cycle and where the cash goes.
KRYS valuation history
KRYS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KRYS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KRYS price vs earnings per share
KRYS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $7.38B | $4.66B | $3.44B | $2.02B | $1.55B | $1.13B | $880.6M | $232.8M | — | — |
| Enterprise value | $6.57B | $4.07B | $2.92B | $1.65B | $1.12B | $867.5M | $690.2M | $121.0M | — | — |
| P/E ratio | 36.0 | 52.3 | 314.9 | — | — | — | — | — | — | — |
| Price / sales | 19.0 | 16.0 | 67.9 | — | — | — | — | 226.7 | — | — |
| Price / book | 6.1 | 4.9 | 4.4 | 3.9 | 2.6 | 3.9 | 4.3 | 2.1 | — | — |
| Price / free cash flow | 39.1 | 39.1 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 36.8 | 37.7 | — | — | — | — | — | — | — | — |
| EV / sales | 16.9 | 14.0 | 57.6 | — | — | — | — | 117.9 | — | — |
| EV / EBITDA | 33.5 | 37.0 | — | — | — | — | — | — | — | — |
| EV / free cash flow | 34.8 | 34.1 | — | — | — | — | — | — | — | — |
| Earnings yield | 2.8% | 1.9% | 0.3% | −6.9% | −4.5% | −2.9% | −2.2% | −4.7% | — | — |
| Free cash flow yield | 2.6% | 2.6% | −2.9% | −7.6% | −7.5% | −3.6% | −2.9% | −5.0% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $246.54 | $156.66 | $124.06 | $79.22 | $69.95 | $60.00 | $55.38 | $20.78 | $10.52 | — |
| Per share | ||||||||||
| Revenue per share | $12.99 | $9.77 | $1.83 | $0.00 | $0.00 | $0.00 | $0.00 | $0.09 | — | — |
| Earnings per share | $6.84 | $3.00 | $0.39 | −$5.49 | −$3.13 | −$1.71 | −$1.20 | −$0.97 | — | — |
| Operating cash flow per share | $6.71 | $4.15 | −$3.20 | −$3.95 | −$2.16 | −$1.39 | −$1.18 | −$0.84 | — | — |
| Free cash flow per share | $6.31 | $4.01 | −$3.63 | −$6.02 | −$5.24 | −$2.18 | −$1.58 | −$1.04 | — | — |
| Cash per share | $27.64 | $20.09 | $19.18 | $14.87 | $19.74 | $14.44 | $12.18 | $9.98 | — | — |
| Book value per share | $40.72 | $31.82 | $28.06 | $20.49 | $26.74 | $15.55 | $12.76 | $10.11 | — | — |
| Tangible book value per share | $40.72 | $31.82 | $28.06 | $20.49 | $26.74 | $15.55 | $12.76 | $10.11 | — | — |
| Capex per share | $0.40 | $0.14 | $0.43 | $2.08 | $3.08 | $0.79 | $0.40 | $0.20 | — | — |
| Debt per share | $0.31 | $0.24 | $0.29 | $0.35 | $0.36 | $0.61 | $0.21 | — | — | — |
| Shares outstanding | 30.0M | 29.7M | 27.8M | 25.5M | 22.2M | 18.8M | 15.9M | 11.2M | — | — |
| Change in shares outstanding | +0.7% | +7.2% | +8.9% | +14.8% | +18.1% | +18.2% | +41.9% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 18.9% | 10.3% | 1.7% | −25.1% | −15.7% | −13.0% | −12.1% | −13.4% | −31.8% | −397.9% |
| Return on invested capital (ROIC) | 42.6% | 20.1% | −45.8% | −72.7% | −55.1% | −116.2% | −250.0% | — | — | −432.0% |
| Return on assets (ROA) | 17.1% | 9.5% | 1.6% | −23.6% | −14.8% | −12.4% | −11.7% | −13.1% | −30.3% | −52.7% |
| Return on tangible assets | 15.4% | 8.4% | 1.3% | −25.1% | −11.1% | −10.3% | −9.1% | −9.4% | −15.8% | −52.7% |
| Free cash flow margin | 48.5% | 41.0% | −198.4% | — | — | — | — | — | — | — |
| Income quality (OCF / net income) | 0.98 | 1.38 | −8.12 | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $9.3M | $7.3M | $8.1M | $8.9M | $8.0M | $11.5M | $3.3M | — | $0 | $1.8M |
| Cash & short-term investments | $827.8M | $597.5M | $532.2M | $379.2M | $438.1M | $271.3M | $193.7M | $111.8M | $49.6M | $1.9M |
| Net debt | −$818.5M | −$590.3M | −$524.1M | −$370.2M | −$430.1M | −$259.7M | −$190.4M | −$111.8M | −$49.6M | −$80,000 |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.04 | 0.02 | — | 0.00 | 6.38 |
| Debt / assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.04 | 0.02 | — | 0.00 | 0.84 |
| Net debt / EBITDA | −4.18 | −5.37 | — | — | — | — | — | — | — | — |
| Current ratio | 9.95 | 7.28 | 17.76 | 13.30 | 17.18 | 17.80 | 58.88 | 43.39 | 77.99 | 50.44 |
| Quick ratio | 9.56 | 7.02 | 17.55 | 13.30 | 17.18 | 17.80 | 58.88 | 43.39 | 77.99 | 50.44 |
| Interest coverage | — | — | — | -27.8 | -45.8 | -39.7 | — | -11.6 | -1.5 | -163.3 |
| Working capital | $921.7M | $640.0M | $554.8M | $354.9M | $416.5M | $259.6M | $192.6M | $110.1M | $49.3M | $2.1M |
| Invested capital | $401.1M | $356.1M | $254.6M | $152.0M | $163.5M | $32.4M | $12.5M | $1.5M | −$117,000 | $209,000 |
| Tangible asset value | $1.22B | $946.4M | $778.6M | $522.2M | $593.6M | $292.1M | $202.9M | $113.2M | $49.5M | $289,000 |
| Net current asset value | $910.4M | $632.6M | $548.2M | $347.6M | $409.5M | $256.3M | $189.8M | $109.8M | $49.3M | $276,000 |
| Graham number | $79.16 | $46.33 | $15.77 | — | — | — | — | — | — | — |
| Graham net-net per share | $27.69 | $19.50 | $19.01 | $13.45 | $18.26 | $13.44 | $11.80 | $9.72 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | — |
| Share buybacks (net) | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 3.1% | 1.5% | 23.3% | — | — | — | — | 217.5% | — | — |
| Capex / operating cash flow | 5.9% | 3.4% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 1.82 | 0.63 | 2.36 | 13.07 | 24.68 | 8.02 | 6.57 | 15.84 | 9.13 | 7.50 |
| Stock-based compensation / revenue | 14.0% | 16.9% | 78.8% | — | — | — | — | 77.1% | — | — |
| R&D / revenue | 14.9% | 18.4% | 91.6% | — | — | — | — | 755.7% | — | — |
| SG&A / revenue | 37.7% | 39.1% | 194.1% | — | — | — | — | 404.6% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 108.9 | 92.2 | 151.3 | — | — | — | — | — | — | — |
| Days of inventory on hand | 424.9 | 304.7 | 412.0 | — | — | — | — | — | — | — |
| Days payables outstanding | 52.2 | 62.2 | 343.9 | 557.1 | 692.2 | 308.2 | 357.7 | 1,399.2 | 1,864.7 | 7,665.0 |
| Cash conversion cycle (days) | 481.6 | 334.7 | 219.5 | — | — | — | — | — | — | — |
| Receivables turnover | 3.35 | 3.96 | 2.41 | — | — | — | — | — | — | — |
| Payables turnover | 7.00 | 5.87 | 1.06 | 0.66 | 0.53 | 1.18 | 1.02 | 0.26 | 0.20 | 0.05 |
| Inventory turnover | 0.86 | 1.20 | 0.89 | — | — | — | — | — | — | — |
| Asset turnover | 0.33 | 0.31 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Average receivables | $116.1M | $73.4M | $21.0M | $0 | — | — | — | — | — | — |
| Average payables | $4.1M | $3.4M | $2.9M | $6.2M | $5.3M | $1.6M | $954,500 | $540,500 | $117,500 | $42,000 |
| Average inventory | $33.5M | $16.7M | $3.5M | $0 | — | — | — | — | $0 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KRYS's annual financial statements (latest annual report filed February 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KRYS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Krystal Biotech traded at 36.0 times earnings, against a 10-year median of 52.3. Based on the latest twelve months, the trailing P/E is 39.7 and the forward P/E is 46.9. Krystal Biotech earned a return on equity of 18.9% and a return on invested capital of 42.6% in fiscal 2025. It ended the year with $9.3 million of debt and $827.8 million in cash and short-term investments, a net cash position of $818.5 million.
See the KRYS income statement, the KRYS chart for price history, or the KRYS stock overview for the latest quote and news.
KRYS key metrics FAQ
What is Krystal Biotech's P/E ratio?
Krystal Biotech's trailing P/E ratio is 39.7 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 46.9. At the end of fiscal 2025 it was 36.0, compared with a 10-year median of 52.3.
What is Krystal Biotech's EV/EBITDA?
Krystal Biotech's enterprise value was 33.5 times EBITDA at the end of fiscal 2025 (enterprise value $6.6 billion, EBITDA $196.0 million); the current EV/EBITDA is 45.4.
What is Krystal Biotech's return on equity?
Krystal Biotech's return on equity (ROE) was 18.9% in fiscal 2025: net income of $204.8 million on average shareholders' equity of $1.1 billion.
What is Krystal Biotech's ROIC?
Krystal Biotech's return on invested capital was 42.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Krystal Biotech have?
Krystal Biotech had total debt of $9.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Krystal Biotech's free cash flow yield?
Krystal Biotech generated $188.9 million of free cash flow in fiscal 2025, a free cash flow yield of 2.6% on its market value at year-end ($7.4 billion).
What is Krystal Biotech's current ratio?
Krystal Biotech's current ratio was 9.95 at the end of fiscal 2025: current assets were 9.95 times current liabilities.